Adrian V. Lee

Adrian V. Lee

Auto-generated profile, based on publicly available information

Adrian V. Lee

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
SOSayali S. Onkar
Sayali S. Onkar
NCNeil Carleton
Neil Carleton
PLPeter C. Lucas
Peter C. Lucas
TBTullia C. Bruno
Tullia C. Bruno
ALAdrian V. Lee
Adrian V. Lee
SOSteffi Oesterreich
Steffi Oesterreich
Breast cancer, the most common type of cancer affecting women, encompasses a collection of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical presentation, disease trajectories, treatment options, and outcomes. Immunotherapy has revolutionized treatment for some solid tumors but has shown limited promise for breast cancers. In this review, we summarize recent advances in our understanding of the complex interactions between tumor and immune cells in subtypes of breast cancer at the cellular and microenvironmental levels. We aim to provide a perspective on opportunities for future immunotherapy agents tailored to specific features of each subtype of breast cancer. Significance: Although there are currently over 200 ongoing clinical trials testing immunotherapeutics, such as immune-checkpoint blockade agents, these are largely restricted to the triple-negative and HER2+ subtypes and primarily focus on T cells. With the rapid expansion of new in vitro, in vivo, and clinical data, it is critical to identify and highlight the challenges and opportunities unique for each breast cancer subtype to drive the next generation of treatments that harness the immune system.

24 April 2015 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
SFSusan M. Farabaugh
Susan M. Farabaugh
DBDavid N. Boone
David N. Boone
ALAdrian V. Lee
Adrian V. Lee
Insulin-like growth factor (IGF) signaling is fundamental for growth and survival. A large body of evidence (laboratory, epidemiological, and clinical) implicates the exploitation of this pathway in cancer. Up to 50% of breast tumors express the activated form of the IGF1 receptor (IGF1R). Breast cancers are categorized into subtypes based upon hormone and ERRB2 receptor expression and/or gene expression profiling. Even though IGF1R influences tumorigenic phenotypes and drug resistance across all breast cancer subtypes, it has specific expression and function in each. In some subtypes, IGF1R levels correlate with a favorable prognosis, while in others it is associated with recurrence and poor prognosis, suggesting different actions based upon cellular and molecular contexts. In this review, we examine IGF1R expression and function as it relates to breast cancer subtype and therapy-acquired resistance. Additionally, we discuss the role of IGF1R in stem cell maintenance and lineage differentiation and how these cell fate influences may alter the differentiation potential and cellular composition of breast tumors.

29 February 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PWPeilu Wang
Peilu Wang
ABAmir Bahreini
Amir Bahreini
RGRekha Gyanchandani
Rekha Gyanchandani
PLPeter C. Lucas
Peter C. Lucas
RHRyan J. Hartmaier
Ryan J. Hartmaier
SOSteffi Oesterreich
Steffi Oesterreich
Purpose: Given the clinical relevance of ESR1 mutations as potential drivers of resistance to endocrine therapy, this study used sensitive detection methods to determine the frequency of ESR1 mutations in primary and metastatic breast cancer, and in cell-free DNA (cfDNA). Experimental Design: Six ESR1 mutations (K303R, S463P, Y537C, Y537N, Y537S, D538G) were assessed by digital droplet PCR (ddPCR), with lower limits of detection of 0.05% to 0.16%, in primary tumors (n = 43), bone (n = 12) and brain metastases (n = 38), and cfDNA (n = 29). Correlations between ESR1 mutations in metastatic lesions and single (1 patient) or serial blood draws (4 patients) were assessed. Results: ESR1 mutations were detected for D538G (n = 13), Y537S (n = 3), and Y537C (n = 1), and not for K303R, S463P, or Y537N. Mutation rates were 7.0% (3/43 primary tumors), 9.1% (1/11 bone metastases), 12.5% (3/24 brain metastases), and 24.1% (7/29 cfDNA). Two patients showed polyclonal disease with more than one ESR1 mutation. Mutation allele frequencies were 0.07% to 0.2% in primary tumors, 1.4% in bone metastases, 34.3% to 44.9% in brain metastases, and 0.2% to 13.7% in cfDNA. In cases with both cfDNA and metastatic samples (n = 5), mutations were detected in both (n = 3) or in cfDNA only (n = 2). Treatment was associated with changes in ESR1 mutation detection and allele frequency. Conclusions: ESR1 mutations were detected at very low allele frequencies in some primary breast cancers, and at high allele frequency in metastases, suggesting that in some tumors rare ESR1-mutant clones are enriched by endocrine therapy. Further studies should address whether sensitive detection of ESR1 mutations in primary breast cancer and in serial blood draws may be predictive for development of resistant disease. Clin Cancer Res; 22(5); 1130–7. ©2015 AACR. See related commentary by Gu and Fuqua, p. 1034

1 May 2017 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
NPNolan Priedigkeit
Nolan Priedigkeit
RHRyan J. Hartmaier
Ryan J. Hartmaier
YCYijing Chen
Yijing Chen
DVDamir Varešlija
Damir Varešlija
ABAhmed Basudan
Ahmed Basudan
ALAdrian V. Lee
Adrian V. Lee
Brain metastases (BrM) occur in 10% to 15% of patients with metastatic breast cancer (BrCa) and present a major clinical challenge, highlighted by a poor 8.5-month median overall survival.1 Limited therapeutic options exist for patients with BrM and current management consists of surgical resection, radiation therapy, and chemotherapy. ERBB2/HER2-positive BrM have demonstrated encouraging responses to ERBB2/HER2-targeted therapies in recent clinical trials.2 Unfortunately, in patients with ERBB2/HER2-negative BrM, no targeted therapies have shown even modest benefits.3

23 May 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ABAmir Bahreini
Amir Bahreini
ZLZheqi Li
Zheqi Li
PWPeilu Wang
Peilu Wang
KLKevin M. Levine
Kevin M. Levine
NTNilgun Tasdemir
Nilgun Tasdemir
SOSteffi Oesterreich
Steffi Oesterreich
Mutations in the estrogen receptor alpha (ERα) 1 gene (ESR1) are frequently detected in ER+ metastatic breast cancer, and there is increasing evidence that these mutations confer endocrine resistance in breast cancer patients with advanced disease. However, their functional role is not well-understood, at least in part due to a lack of ESR1 mutant models. Here, we describe the generation and characterization of genome-edited T47D and MCF7 breast cancer cell lines with the two most common ESR1 mutations, Y537S and D538G. Genome editing was performed using CRISPR and adeno-associated virus (AAV) technologies to knock-in ESR1 mutations into T47D and MCF7 cell lines, respectively. Various techniques were utilized to assess the activity of mutant ER, including transactivation, growth and chromatin-immunoprecipitation (ChIP) assays. The level of endocrine resistance was tested in mutant cells using a number of selective estrogen receptor modulators (SERMs) and degraders (SERDs). RNA sequencing (RNA-seq) was employed to study gene targets of mutant ER. Cells with ESR1 mutations displayed ligand-independent ER activity, and were resistant to several SERMs and SERDs, with cell line and mutation-specific differences with respect to magnitude of effect. The SERD AZ9496 showed increased efficacy compared to other drugs tested. Wild-type and mutant cell co-cultures demonstrated a unique evolution of mutant cells under estrogen deprivation and tamoxifen treatment. Transcriptome analysis confirmed ligand-independent regulation of ERα target genes by mutant ERα, but also identified novel target genes, some of which are involved in metastasis-associated phenotypes. Despite significant overlap in the ligand-independent genes between Y537S and D538G, the number of mutant ERα-target genes shared between the two cell lines was limited, suggesting context-dependent activity of the mutant receptor. Some genes and phenotypes were unique to one mutation within a given cell line, suggesting a mutation-specific effect. Taken together, ESR1 mutations in genome-edited breast cancer cell lines confer ligand-independent growth and endocrine resistance. These biologically relevant models can be used for further mechanistic and translational studies, including context-specific and mutation site-specific analysis of the ESR1 mutations.

1 February 2022 in The Astrophysical Journal Supplement Series
Verified
Journal Article
Open access
JSJ. A. Sobrin
J. A. Sobrin
AAA. J. Anderson
A. J. Anderson
ABA. N. Bender
A. N. Bender
BBB. A. Benson
B. A. Benson
DDD. Dutcher
D. Dutcher
MYM. R. Young
M. R. Young
SPT-3G is the third survey receiver operating on the South Pole Telescope dedicated to high-resolution observations of the cosmic microwave background (CMB). Sensitive measurements of the temperature and polarization anisotropies of the CMB provide a powerful data set for constraining cosmology. Additionally, CMB surveys with arcminute-scale resolution are capable of detecting galaxy clusters, millimeter-wave bright galaxies, and a variety of transient phenomena. The SPT-3G instrument provides a significant improvement in mapping speed over its predecessors, SPT-SZ and SPTpol. The broadband optics design of the instrument achieves a 430 mm diameter image plane across observing bands of 95, 150, and 220 GHz, with 1.2′ FWHM beam response at 150 GHz. In the receiver, this image plane is populated with 2690 dual-polarization, trichroic pixels (∼16,000 detectors) read out using a 68× digital frequency-domain multiplexing readout system. In 2018, SPT-3G began a multiyear survey of 1500 deg2 of the southern sky. We summarize the unique optical, cryogenic, detector, and readout technologies employed in SPT-3G, and we report on the integrated performance of the instrument.